证券代码：688161 证券简称：威高骨科 公告编号：2025-044 山东威高骨科材料股份有限公司 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 11 月 17 日 （二） 股东会召开的地点：山东威高骨科材料股份有限公司会议室（威海市旅 游度假区香江街 26 号） （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 61 | | --- | --- | | 普通股股东人数 | 61 | | 2、出席会议的股东所持有的表决权数量 | 336,465,061 | | 普通股股东所持有表决权数量 | 336,465,061 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 84.1162 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 84.1162 | （四） 表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容 ...

北京市中伦（深圳）律师事务所 关于山东威高骨科材料股份有限公司 2025 年第二次临时股东会的 北京市中伦（深圳）律师事务所 关于山东威高骨科材料股份有限公司 二〇二五年十一月 法律意见书 2025 年第二次临时股东会的 法律意见书 致：山东威高骨科材料股份有限公司 法律意见书 根据中国证监会发布的《上市公司股东会规则》（下称"《股东会规则》"） 的有关规定，北京市中伦（深圳）律师事务所（下称"本所"）接受山东威高骨 科材料股份有限公司（下称"公司"）的委托，指派律师出席公司 2025 年第二次 临时股东会（下称"本次股东会"），并就本次股东会的召集和召开程序、召集人 资格、出席和列席会议人员资格、表决程序及表决结果等事宜发表法律意见。 本所及经办律师依据《中华人民共和国证券法》《律师事务所从事证券法律 业务管理办法》和《律师事务所证券法律业务执业规则》等规定及本法律意见书 出具日以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和 诚实信用原则，进行了充分的核查验证，保证本法律意见所认定的事实真实、准 确、完整，所发表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者 重大遗漏，并承担相应法 ...

Core Viewpoint - Weigao Orthopedics has shown a positive performance in terms of stock price and trading volume, with significant financing activities indicating strong investor interest [1][2]. Financing Activities - On November 14, Weigao Orthopedics experienced a stock price increase of 1.24%, with a trading volume of 71.93 million yuan. The financing buy-in amount for the day was 14.26 million yuan, while the financing repayment was 12.78 million yuan, resulting in a net financing buy of 1.47 million yuan [1]. - As of November 14, the total financing and securities lending balance for Weigao Orthopedics was 150 million yuan, with the financing balance at 149 million yuan, accounting for 1.20% of the circulating market value, which is above the 90th percentile level over the past year [1]. Shareholder Information - As of September 30, the number of shareholders for Weigao Orthopedics reached 10,700, an increase of 18.33% compared to the previous period. The average circulating shares per person decreased by 15.49% to 37,418 shares [2]. - The company has distributed a total of 575 million yuan in dividends since its A-share listing, with 367 million yuan distributed over the past three years [3]. Financial Performance - For the period from January to September 2025, Weigao Orthopedics reported a revenue of 1.106 billion yuan, reflecting a year-on-year growth of 2.12%. The net profit attributable to the parent company was 207 million yuan, showing a significant increase of 26.24% year-on-year [2]. Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the seventh-largest circulating shareholder, holding 3.4373 million shares, an increase of 392,000 shares from the previous period. Additionally, Penghua Medical Technology Stock A entered as the tenth-largest circulating shareholder with 1.0961 million shares [3].

Investment Rating - The industry investment rating is maintained as "Outperform the Market" [2][57]. Core Insights - The orthopedic consumables sector has shown continuous improvement in performance during the first three quarters of 2025, with a positive trend in overseas expansion [3][10]. - The overall revenue of the orthopedic consumables sector increased by 17% year-on-year for Q1-Q3 2025, with net profit attributable to shareholders rising by 81% [5][10]. - The gross profit margin for the sector improved to 66% in Q1-Q3 2025, reflecting effective cost control and optimization [4][10]. - The trend of companies actively pursuing international markets is expected to become a significant growth driver [10][27]. Summary by Sections 1. Orthopedic Consumables Q3 2025 Report Analysis - The orthopedic consumables sector's revenue for Q1-Q3 2025 reached 49.18 billion, with a year-on-year growth of 17% [9]. - The gross profit margin for Q3 2025 was reported at 67%, an increase of 2.06 percentage points compared to the previous year [10]. - The net profit attributable to shareholders for Q3 2025 doubled year-on-year, indicating significant performance improvement [10]. 2. Segment Analysis - The joint business segment has seen stable growth due to the continuation of centralized procurement and an increase in both volume and price for leading companies [19][24]. - The spinal segment is experiencing a steady execution of centralized procurement, with leading domestic brands increasing their market share [25]. - The trend of domestic companies expanding overseas is gaining momentum, with a focus on product innovation and international development [27][29]. 3. Related Company Q3 Report Summary - Major companies in the sector, such as Dabo Medical, Weigao Orthopedics, and Spring Medical, have shown strong revenue growth and profitability improvements in Q3 2025 [12][41][45]. - Dabo Medical reported a revenue of 18.76 billion, up 22.69% year-on-year, with a net profit of 4.25 billion, reflecting a 77.03% increase [45]. - Spring Medical achieved a remarkable revenue growth of 109.5% in Q3 2025, turning a previous loss into a profit of 770.6 million [33].

证券代码：688161 证券简称：威高骨科 山东威高骨科材料股份有限公司 2025 年第二次临时股东会 会议资料 二零二五年十一月 | | | 山东威高骨科材料股份有限公司 2025 年第二次临时股东会会议资料 2025 年第二次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》 《山东威高骨科材料股份有限公司章程》等相关规定，山东威高骨科材料股份 有限公司（以下简称"公司"）特制定 2025 年第二次临时股东会会议须知： 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工 作人员将对出席会议人员的身份进行必要的核对工作，请被核对者给予配合。 出席会议的股东及股东代理人须在会议召开前 30 分钟到会议现场办理签到 手续，并请按规定出示证券账户卡、身份证明文件或法人单位证明、授权委托 书等，经验证后领取会议资料，方可出席会议。 经公司审核，符合条件参加本次会议的股东、股东代理人、公司董事、高 级管理人员、聘任律师及董事会邀请的人员等可进入会场，公司有权拒绝不符 合条件的人员进入会场。 会议开始后 ...

Core Viewpoint - The report highlights the target price increases for several listed companies, indicating strong potential growth in various sectors, particularly in medical devices, home appliances, and engineering machinery [2][4]. Group 1: Target Price Increases - Weigao Orthopedics, Gree Electric Appliances, and Sany Heavy Industry have the highest target price increases of 46.70%, 40.99%, and 37.03% respectively, indicating strong market confidence in these companies [2][4]. - The target prices for Gree Electric Appliances and Sany Heavy Industry are set at 56.00 yuan and 29.90 yuan respectively [4]. Group 2: Rating Adjustments - On November 5, Citic Securities upgraded the rating of Trina Solar from "Hold" to "Buy," reflecting increased optimism about the company's future performance [5][6]. - Additionally, the rating for Nengke Technology was also upgraded from "Hold" to "Buy" by Industrial Securities [5][6]. Group 3: New Coverage - Salt Lake Co. received a "Buy" rating from Tianfeng Securities, marking its first coverage, indicating a positive outlook for the agricultural chemical sector [7][8]. - Haoyang Co. was also newly covered with an "Increase" rating by Industrial Securities, suggesting potential growth in the specialized equipment industry [7][8].

Investment Rating - The investment rating for the company is "Outperform the Market" [6][28]. Core Views - The company has achieved a revenue growth of 10% in Q3 2025, with a net profit growth of 8% after excluding share-based payment expenses. For the first three quarters of 2025, the company reported a revenue of 1.106 billion (up 2.1%) and a net profit of 207 million (up 26.2%) [1][3]. - The sales model transformation has led to a focus on core business lines, driving revenue and sales growth across multiple product lines. The joint product line saw a revenue of 273 million (down 9%) but a volume increase of 15% in the first three quarters [2][3]. - The company has improved its profitability metrics, with a net profit margin of 19.1% (up 3.5 percentage points) and a significant reduction in sales expense ratio by 7.9 percentage points to 26.4% [3][6]. Financial Performance Summary - For the first three quarters of 2025, the company achieved a gross margin of 64.6% (down 0.1 percentage points) and an operating cash flow of 250 million (up 31.9%), maintaining a healthy ratio of operating cash flow to net profit at 121% [3][26]. - The company has slightly adjusted its profit forecast for 2025-2027, expecting net profits of 281 million, 325 million, and 378 million respectively, reflecting year-on-year growth rates of 25.6%, 15.5%, and 16.5% [3][26]. - The current stock price corresponds to a price-to-earnings (PE) ratio of 41.4 for 2025, 35.8 for 2026, and 30.8 for 2027, indicating the company's potential for platform growth and risk resistance [3][26].

Core Insights - On November 5, 2023, brokerage firms issued target prices for listed companies, with notable increases for Weigao Orthopedics, Gree Electric Appliances, and Sany Heavy Industry, showing target price increases of 46.70%, 40.99%, and 37.03% respectively, across the medical device, white goods, and engineering machinery sectors [1][2]. Target Price Increases - Weigao Orthopedics (688161) received a target price of 42.63 yuan with a target increase of 46.70% from Dongfang Securities [2] - Gree Electric Appliances (000651) has a target price of 56.00 yuan, reflecting a 40.99% increase from CITIC Securities [2] - Sany Heavy Industry (600031) was assigned a target price of 29.90 yuan, indicating a 37.03% increase from Nomura Orient International Securities [2] - Other companies with significant target price increases include: - Perchaya (603605) with a 36.61% increase - FAW Jiefang (000800) with a 32.09% increase - Oppein Home Group (603833) with a 31.60% increase [2] Brokerage Recommendations - The number of brokerage recommendations for companies on November 5 includes: - Heng Rui Medicine (600276) with 2 recommendations - Platinum New Materials (300811) with 2 recommendations - Kweichow Moutai (600519) with 2 recommendations [3] - Upgrades in ratings include: - Trina Solar (688599) upgraded from "Hold" to "Buy" by CITIC Securities - Nengke Technology (603859) upgraded from "Hold" to "Buy" by Industrial Securities [4] Downgrades and New Coverage - Shanghai Yanpu (605128) was downgraded from "Strong Buy" to "Recommended" by Huachuang Securities [5] - New coverage includes: - Salt Lake Co. (000792) rated "Buy" by Tianfeng Securities - Haoyang Co. (300833) rated "Hold" by Industrial Securities [6]

Group 1 - The core viewpoint of the article highlights significant target price increases for certain companies, with Weigao Orthopedics, Gree Electric Appliances, and Sany Heavy Industry leading the rankings with target price increases of 46.70%, 40.99%, and 37.03% respectively [1] - On November 5, a total of 98 listed companies received recommendations from brokerages, with Heng Rui Medicine, Placo New Materials, and Kweichow Moutai each receiving two recommendations [1] - Shanghai Yanpu's rating was downgraded by Huachuang Securities from "strong buy" to "recommend" on November 5 [1]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 42.63 CNY, based on a 49x PE for 2026 [3][6]. Core Insights - The company demonstrated robust profitability with a notable performance in PRP products, achieving a revenue of 1.11 billion CNY in the first three quarters of 2025, reflecting a year-on-year increase of 2.1% [11]. - The sales model reform has significantly improved profit growth, with a net profit of 210 million CNY in the first three quarters, up 26.2% year-on-year [11]. - The company is expanding its product categories to create a diversified "Orthopedics+" ecosystem, reducing reliance on single products and enhancing long-term competitiveness [11]. Financial Performance Summary - Revenue projections for 2025-2027 are 1.652 billion CNY, 1.860 billion CNY, and 2.072 billion CNY, respectively, with year-on-year growth rates of 13.7%, 12.6%, and 11.4% [5][12]. - The net profit attributable to the parent company is forecasted to be 314 million CNY, 348 million CNY, and 390 million CNY for 2025-2027, with growth rates of 40.5%, 10.7%, and 11.9% [5][12]. - The gross margin is expected to remain stable around 65.5% to 65.2% from 2025 to 2027, while the net margin is projected to increase from 19.0% in 2025 to 18.8% in 2027 [5][12].